Phapros (PEHA) Net Profit Surges 311.58% in Q3 2026, Driven by 15.07% Sales Growth

JAKARTA, November 2, 2026 – PT Phapros Tbk (PEHA), one of Indonesia's leading pharmaceutical companies and a member of the State-Owned Pharmaceutical Holding Group, once again delivered strong financial performance in the third quarter of 2026. Phapros' net profit surged 311.58%, more than quadrupling to IDR 31.60 billion, while sales grew 15.07% year-on-year (YoY) to IDR 786.57 billion.

The Company also successfully improved its operational efficiency. Earnings before interest, taxes, depreciation, and amortization (EBITDA) for January–September 2026 increased by 30.26% to IDR 117.66 billion compared with the corresponding period in 2025. The EBITDA margin rose to 15% from 13.2%, reflecting improved manufacturing efficiency and stronger profitability. Gross profit margin also improved, supported by enhancements to the product portfolio and greater efficiency in manufacturing processes.

Phapros has maintained a sustainable financial growth trajectory since 2025 despite global and domestic challenges facing the pharmaceutical industry. In 2025, the Company recorded sales of IDR 940.88 billion, representing a 26.34% YoY increase. This positive momentum continued through September 2026, with sales reaching IDR 786.57 billion, compared with IDR 683.58 billion in January–September 2025.

Cost Efficiency Amid Exchange Rate Fluctuations

The Company successfully maintained cost efficiency, keeping its cost of goods sold (COGS) under control despite fluctuations in the Indonesian rupiah exchange rate. During the first nine months of 2026, COGS amounted to IDR 384.04 billion, increasing by only 11.04% from IDR 345.86 billion in the corresponding period of the previous year. The COGS-to-sales ratio declined to 48.8% from 50.6%, indicating improved manufacturing efficiency.

The combination of sustained sales growth and improved operational efficiency drove gross profit up by 19.19% to IDR 402.53 billion from IDR 337.72 billion. Gross profit margin increased to 51.2% from 49.4%.

Intan Abdams Katoppo, President Director of PT Phapros Tbk, stated that the Company remains on the right track toward sustaining long-term profitability. According to her, the Company's performance growth through September 2026 reflects the effective execution of several strategic initiatives, including strengthening working capital, implementing more disciplined cost controls, enhancing its product and business portfolios, and transforming business systems and processes. These initiatives have been implemented since 2025 and continue to undergo regular evaluation and review.

"We are optimistic that Phapros' positive financial performance will continue through the end of this year. Furthermore, supported by our strong fundamentals, we are confident that this growth momentum will extend into next year. The improvement in our EBITDA margin demonstrates greater operational efficiency and stronger profitability, enabling Phapros to continue contributing to the health and well-being of the Indonesian people," said Intan on November 2, 2026.

Significant Profit Growth

Phapros recorded operating expenses of IDR 321.15 billion during January–September 2026, while operating profit increased by 55.90% to IDR 80.97 billion, compared with IDR 51.94 billion in the corresponding period of 2025.

Profit before tax rose by 233.59%, more than tripling to IDR 48.65 billion, compared with IDR 14.58 billion during January–September 2025. Net profit increased significantly by 311.58% to IDR 31.60 billion from IDR 7.68 billion in the same period of the previous year.

Phapros' financial fundamentals are currently supported by strong cash flow. Net cash flow from operating activities increased by 142.85% to IDR 129.96 billion from IDR 53.51 billion. Cash and cash equivalents as of September 30, 2026, rose by 70.54% to IDR 157.54 billion from IDR 92.38 billion as of September 30, 2025. Total assets increased by 4.74% to IDR 1.45 trillion from IDR 1.39 trillion as of December 31, 2025.

As the third quarter of 2026 concludes, PT Phapros Tbk continues to strengthen its foundations for growth through disciplined business management, the development of a competitive product portfolio, and improvements in operational efficiency and reliability. Supported by its pharmaceutical manufacturing capabilities, distribution network, and commitment to good corporate governance, Phapros seeks to capture market opportunities while delivering healthy and sustainable growth.

Looking ahead, the Company will remain focused on creating long-term value for all stakeholders, including its shareholders. Through a clear strategic direction and consistent execution, Phapros moves forward with confidence in strengthening its competitiveness and building sustainable corporate value, positioning the Company to close 2026 on a strong and positive note.